Atika Capital Management LLC Sells 9,702 Shares of ABIVAX Société Anonyme (NASDAQ:ABVX)

Atika Capital Management LLC decreased its holdings in ABIVAX Société Anonyme (NASDAQ:ABVX) by 8.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 103,929 shares of the company’s stock after selling 9,702 shares during the quarter. Atika Capital Management LLC’s holdings in ABIVAX Société Anonyme were worth $761,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Franklin Resources Inc. raised its holdings in shares of ABIVAX Société Anonyme by 10.7% in the fourth quarter. Franklin Resources Inc. now owns 1,466,062 shares of the company’s stock valued at $10,732,000 after buying an additional 141,710 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in ABIVAX Société Anonyme in the 4th quarter valued at about $5,336,000. Point72 Asset Management L.P. raised its stake in shares of ABIVAX Société Anonyme by 28.2% in the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock worth $6,254,000 after acquiring an additional 119,300 shares during the last quarter. abrdn plc lifted its position in shares of ABIVAX Société Anonyme by 34.1% during the fourth quarter. abrdn plc now owns 424,181 shares of the company’s stock worth $3,105,000 after purchasing an additional 107,750 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in shares of ABIVAX Société Anonyme by 82.6% during the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after purchasing an additional 5,900 shares during the last quarter. Institutional investors and hedge funds own 47.91% of the company’s stock.

ABIVAX Société Anonyme Stock Performance

NASDAQ:ABVX opened at $5.32 on Friday. ABIVAX Société Anonyme has a 12-month low of $5.16 and a 12-month high of $16.63. The stock’s fifty day simple moving average is $6.77 and its 200-day simple moving average is $8.14.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Morgan Stanley reaffirmed an “equal weight” rating and set a $12.00 price objective on shares of ABIVAX Société Anonyme in a report on Thursday, March 20th. JMP Securities reaffirmed a “market outperform” rating and set a $33.00 price target on shares of ABIVAX Société Anonyme in a research note on Friday, January 10th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, ABIVAX Société Anonyme currently has a consensus rating of “Buy” and an average target price of $38.00.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.